Quartz·1 min read·medium
Sionna Therapeutics stock plunged 92% after its cystic fibrosis drug flopped in a mid-stage trial
✦AI Summary
Sionna Therapeutics saw its stock price drop by 92% following the failure of its cystic fibrosis drug, SION-719, in a mid-stage clinical trial. The company has announced it will discontinue the development of the drug as an add-on therapy.
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in